RE:RE:RE:Latest update from company
Hi Looneytunes ...again, NOT to defend them, I'm also a shareholder and just as frustrated of delays as everyone else.
Price of shares going down while "they" issue more shares and warrants could be helping them, but this happens all the time with startups who need more funding along the way. The CVR Global vs Medical was borderline and I knew upfront when I purchased first shares ...back then I knew it was already a 50-50 split any way you looked at it ...the sort out with additional shares/warrants issued wasn't sunny, especially that they did not sort it out outright but have to pay royalties (NOT happy of that one!) but at least it was then sorted. Better that way than the original 50-50 split if you think about it. Though still not liking/fully understanding CVR Global retaining some intellectual property, etc...
Trying to have an objective/pragmatic view of what's happening and not an emotional one, when they established their timeline a long time ago, it was difficult to plan the unpredictable, especially over the course of "years" ...and in light of new and recent upcoming TUV standard that was announced to come into effect in near future (Jan 1st I think...), the logical thing to do was what they did, not go for FDA submittal right away so they don't get further delays down the line - just like many companies/devices that were also going in to get approval before new standard comes into effect, which created the TUV back log in the first place.
Again, not trying to defend them one bit, I too am VERY frustrated of delays and especially of additional shares/warrants, etc... But be ready, there will be a lot more of those as we move along, it's just the nature of startups. We're here for the long haul with the idea of buying low/selling high ...and we hang on because of the large potential gain of a potential killer app in a very large market.
"If" we do attain FDA approval, then share price will spike and will be too late on the buy low/sell high, it's the eternal risk-reward question. Even post-FDA approval, you can pretty much expect there will be more shares/warrants issued to help fund early production/marketing/sales and share price will probably go back down from spike ...and on and on... It's a long road... I don't think you can hope for a quick gain on this, but more so a substantial gain over time down the line ...I think that's why we're all in here. I did like their sales projections and how somewhat conservative they were, even after three years out - particularly of the overall numbers then. If one believed in the concept in the first place, the real question should probably be "should I buy more while it's low...er?"
No I have not been able to convince myself to put more money in ...though my little voice tells me I should as next news should likely be FDA submittal ...which should create a short term spike, then again an emotional and unwarranted spike as nothing of the original premisse and original story will have changed with an FDA submittal ...it's all about FDA "approval" as with all biotech...
In the meantime, it's very easy to be high-low in our moods along with share price swings, dilution, etc... Surely lots more of that ahead I'm sure - again, the very nature of biotech startups.